Every benefits vendor promises a seamless implementation. Few deliver.   If you've been in HR and benefits long enough, you know the drill: the sales experience is polished, the demos are impressive, and somewhere between contract signing and go-live, things get complicated. Suddenly you're the project manager for a solution you just bought. Meetings multiply. Decisions pile up. Your team absorbs the lift.   Pharmacy benefits is already one of the most complex categories you

As we move through 2026, several high-profile medications are entering the market, promising new options for patients across a range of conditions. We sat down with Dr. Paul Bradley, Chief Medical Officer at Scripta Insights, to get his perspective on just how game-changing these drug launches could be for patients, plan sponsors, and the bigger healthcare landscape. The GLP-1 Competition Heats Up The GLP-1 market continues to dominate headlines, and new drugs from Novo Nordi

Novo Nordisk's oral Wegovy pill is now available, and HR and benefits teams are asking the same questions: Will this reduce costs? Will it improve access? Will members finally stop calling about GLP-1 coverage?   At Scripta, we're already seeing what's happening on the ground—and the reality is more complicated than the headlines suggest. Here's what plan sponsors need to understand as this new formulation enters the market. "Oral" Doesn't Mean Lower Cost or Easier Access   T